[{"id":"297cd590-bacb-40d9-b395-eacfa8bc49d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06949761","created_at":"2025-09-07T01:25:54.516Z","updated_at":"2025-09-07T01:25:54.516Z","phase":"Phase 1/2","brief_title":"A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","source_id_and_acronym":"NCT06949761","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • Qibeian (iparomlimab/tuvonralimab) • QL1203"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-04-29"}]